1) Recombinant hepatic stimulator substance(hHHS)
重组肝刺激因子
2) hepatic stimulator substance
肝刺激因子
1.
Objective To assay the effect of hepatic stimulator substance (HSS) on the expression of EGFR/DNA of human hepatoma cells.
目的检测肝刺激因子 (HSS)对人肝癌细胞EGFR/DNA表达的影响。
3) recombinant human granulocyte colony-stimulating factor
重组人粒细胞刺激因子
1.
Preliminary study on the influence of urea content on recombinant human granulocyte colony-stimulating factor quality;
考察尿素含量对重组人粒细胞刺激因子质量的影响
2.
The Investigation of the Separation and Purification Procedure of Recombinant Human Granulocyte Colony-stimulating Factor;
重组人粒细胞刺激因子（rhG-CSF）的分离纯化工艺研究
4) Hepatic stimulator substance
肝细胞刺激因子
1.
Protection of hepatic stimulator substance against chemotherapeutic liver damage induced by cyclophosphamide in mice inoculated with S_(180) cells;
人肝细胞刺激因子对环磷酰胺致S_(180)荷瘤小鼠肝损伤的保护作用
2.
Objective To establish two fatty liver models of rats: high-fatty diet induced nonalcoholic fatty liver (NAFL), high-fatty diet and alcohol induced compound fatty liver(CFL), to investigate their possible mechanism, and to study the effect of hepatic stimulator substance(HSS) on the two fatty liver models and their possible mechanism after the models were made.
制造模型成功后再用肝细胞刺激因子(HSS)进行治疗,观察其疗效并探讨其作用机理。
3.
Objective To study the therapy effect and possible mechanism of hepatic stimulator substance (HSS) associated Runganling on nonalcoholic fatty liver disease (NAFLD) of rat.
目的 研究肝细胞刺激因子(hepatic stimulator substance,HSS)联合润肝灵方剂对大鼠非酒精性脂肪肝(nonalcoholic fatty liver disease,NAFLD)的治疗作用及可能机制。
5) human hepatic stimulator substance
人肝刺激因子
1.
Objective To establish the prokaryotic expression system for expression of human hepatic stimulator substance.
目的构建人肝刺激因子(human hepatic stimulator substance,hHSS)体外表达体系。
2.
To explore the possibility of prokaryotic expression of human hepatic stimulator substance (hHSS), hHSS gene was inserted in the downstream of glutathion S transferase (GST) in a pET 42a expression vector and recombinant GST hHSS fusion protein was expressed under IPTG induction in BL 21(DE3) cells.
利用基因重组技术 ,构建成人肝刺激因子 (hHSS)和谷胱甘肽转移酶 (GST)融合表达载体 ,转化大肠杆菌BL 2 1(DE3 ) ,以His·Tag亲和层析纯化表达产物 ,FactorXa切割分离hHSS单体 ,并检测其生物学活性。
6) hepatic stimulator substance (HSS)
肝再生刺激因子
补充资料：重组人粒细胞-巨噬细胞集落刺激因子
重组人粒细胞-巨噬细胞集落刺激因子
这是一种调节造血和白细胞功能所必需的清蛋白、可刺激粒细胞和巨噬细胞等白细胞的增殖、分化和活化作用、从而增强造血功能，还能增强中性粒细胞、嗜酸性粒细胞及单核细胞的多种功能，促使效应细胞吞噬和消灭癌细胞等免疫活动增强。适用于治疗和预防化学疗法所引起的白细胞减少症及骨髓功能衰竭病人的白细胞减少。对化疗病人应在化疗停止24小时后开始使用。剂量每日5～10μg/kg，持续7～10天，此后至少间隔48小时再进行下一疗程化疗，骨髓增生异常综合征(MDS)及再生障碍性贫血的应用剂量：每日3μg/kg，每日1次，然后根据白细胞增多效应再调节剂量，维持在所期望白细胞计数水平。用于骨髓移植的剂量：每日5～10μg/kg，静注，每日1次，持续致中性粒细胞计数＞1000/μl达3天以上。此药不良反应最常见为发热，可用扑热息痛缓解，其他较少见的反应有低血压、恶心、水肿、胸痛、骨痛、腹泻、以及过敏反应等。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条